Yu X, et al. - Via a systemic review and meta-analysis of randomized, controlled, multicenter trials, researchers evaluated the efficacy and safety of pregabalin for spinal cord injury (SCI)-induced neuropathic pain. Searching PubMed and EMBASE databases and the Cochrane library in May 2018, they included 5 publications (pregabalin, patients=261, placebo, patients=216) in this study. After at least 4-week’s treatment with pregabalin (flexible dose, 150 to 600 mg/d), pregabalin-treated patients showed reduced pain; improved pain relief; increased adverse events; and reduced Hospital Anxiety and Depression Scale scores compared with placebo-treated patients. As per these results, they suggest pregabalin to be an efficacious and safe treatment option for chronic pain followed SCI.